Gilead Sciences is trading at $169.24 (-3.00%) in the November 5 live session, alongside a sharp broader-market and biotech sell-off.
- XBI fell 5.19%, Nasdaq 4.49%, and S&P 500 3.70%, pointing to risk-off market pressure.
- Gilead beat third-quarter estimates and raised its 2026 product-sales outlook. Reuters reported a Biktarvy Medicare price reduction starting in 2028; neither establishes the reason for this session’s drop.